Cargando…

AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy

Biomarkers for predicting the risk of castration-resistant prostate cancer (CRPC) in men treated with primary androgen deprivation therapy (ADT) are lacking. We investigated whether Zinc-alpha 2 glycoprotein (AZGP1) expression in the diagnostic biopsies of men with hormone-naïve prostate cancer (PCa...

Descripción completa

Detalles Bibliográficos
Autores principales: Winther, Mads Dochedahl, Kristensen, Gitte, Stroomberg, Hein Vincent, Berg, Kasper Drimer, Toft, Birgitte Grønkær, Brooks, James D., Brasso, Klaus, Røder, Martin Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460336/
https://www.ncbi.nlm.nih.gov/pubmed/32726925
http://dx.doi.org/10.3390/diagnostics10080520
_version_ 1783576577934622720
author Winther, Mads Dochedahl
Kristensen, Gitte
Stroomberg, Hein Vincent
Berg, Kasper Drimer
Toft, Birgitte Grønkær
Brooks, James D.
Brasso, Klaus
Røder, Martin Andreas
author_facet Winther, Mads Dochedahl
Kristensen, Gitte
Stroomberg, Hein Vincent
Berg, Kasper Drimer
Toft, Birgitte Grønkær
Brooks, James D.
Brasso, Klaus
Røder, Martin Andreas
author_sort Winther, Mads Dochedahl
collection PubMed
description Biomarkers for predicting the risk of castration-resistant prostate cancer (CRPC) in men treated with primary androgen deprivation therapy (ADT) are lacking. We investigated whether Zinc-alpha 2 glycoprotein (AZGP1) expression in the diagnostic biopsies of men with hormone-naïve prostate cancer (PCa) undergoing primary ADT was predictive of the development of CRPC and PCa-specific mortality. The study included 191 patients who commenced ADT from 2000 to 2011. The AZGP1 expression was evaluated using immunohistochemistry and scored as high or low expression. The risks of CRPC and PCa-specific mortality were analyzed using stratified cumulative incidences and a cause-specific COX regression analysis for competing risk assessment. The median follow-up time was 9.8 (IQR: 6.1–12.7) years. In total, 94 and 97 patients presented with low and high AZGP1 expression, respectively. A low AZGP1 expression was found to be associated with a shorter time to CRPC when compared to patients with a high AZGP1 expression (HR: 1.5; 95% CI: 1.0–2.1; p = 0.03). However, the multivariable analysis demonstrated no added benefit by adding the AZGP1 expression to prediction models for CRPC. No differences for PCa-specific mortality between the AZGP1 groups were observed. In conclusion, a low AZGP1 expression was associated with a shorter time to CRPC for PCa patients treated with first-line ADT but did not add any predictive information besides well-established clinicopathological variables.
format Online
Article
Text
id pubmed-7460336
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74603362020-09-02 AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy Winther, Mads Dochedahl Kristensen, Gitte Stroomberg, Hein Vincent Berg, Kasper Drimer Toft, Birgitte Grønkær Brooks, James D. Brasso, Klaus Røder, Martin Andreas Diagnostics (Basel) Article Biomarkers for predicting the risk of castration-resistant prostate cancer (CRPC) in men treated with primary androgen deprivation therapy (ADT) are lacking. We investigated whether Zinc-alpha 2 glycoprotein (AZGP1) expression in the diagnostic biopsies of men with hormone-naïve prostate cancer (PCa) undergoing primary ADT was predictive of the development of CRPC and PCa-specific mortality. The study included 191 patients who commenced ADT from 2000 to 2011. The AZGP1 expression was evaluated using immunohistochemistry and scored as high or low expression. The risks of CRPC and PCa-specific mortality were analyzed using stratified cumulative incidences and a cause-specific COX regression analysis for competing risk assessment. The median follow-up time was 9.8 (IQR: 6.1–12.7) years. In total, 94 and 97 patients presented with low and high AZGP1 expression, respectively. A low AZGP1 expression was found to be associated with a shorter time to CRPC when compared to patients with a high AZGP1 expression (HR: 1.5; 95% CI: 1.0–2.1; p = 0.03). However, the multivariable analysis demonstrated no added benefit by adding the AZGP1 expression to prediction models for CRPC. No differences for PCa-specific mortality between the AZGP1 groups were observed. In conclusion, a low AZGP1 expression was associated with a shorter time to CRPC for PCa patients treated with first-line ADT but did not add any predictive information besides well-established clinicopathological variables. MDPI 2020-07-27 /pmc/articles/PMC7460336/ /pubmed/32726925 http://dx.doi.org/10.3390/diagnostics10080520 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Winther, Mads Dochedahl
Kristensen, Gitte
Stroomberg, Hein Vincent
Berg, Kasper Drimer
Toft, Birgitte Grønkær
Brooks, James D.
Brasso, Klaus
Røder, Martin Andreas
AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
title AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
title_full AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
title_fullStr AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
title_full_unstemmed AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
title_short AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
title_sort azgp1 protein expression in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460336/
https://www.ncbi.nlm.nih.gov/pubmed/32726925
http://dx.doi.org/10.3390/diagnostics10080520
work_keys_str_mv AT winthermadsdochedahl azgp1proteinexpressioninhormonenaiveadvancedprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT kristensengitte azgp1proteinexpressioninhormonenaiveadvancedprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT stroombergheinvincent azgp1proteinexpressioninhormonenaiveadvancedprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT bergkasperdrimer azgp1proteinexpressioninhormonenaiveadvancedprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT toftbirgittegrønkær azgp1proteinexpressioninhormonenaiveadvancedprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT brooksjamesd azgp1proteinexpressioninhormonenaiveadvancedprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT brassoklaus azgp1proteinexpressioninhormonenaiveadvancedprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT rødermartinandreas azgp1proteinexpressioninhormonenaiveadvancedprostatecancertreatedwithprimaryandrogendeprivationtherapy